TABLE 1.

Characteristics of patients with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia referred for asthma management

	Patients
	1	2	3	4	5	6	7	8	9	10
Age (years)	68	77	76	56	50	71	65	66	55	62
Gender	F	F	F	F	F	F	F	M	F	F
BMI (kg·m−2)	29.4	23.1	22.8	32.3	24.8	26.2	27.6	25.0	25.9	22.7
History of smoking	No	No	No	Yes	No	No	No	No	No	Yes
Dry cough	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cough duration (years)	>30	10	30	10	25	10	>30	12	14	20
≥2 exacerbations within the past 12 months	Yes	No	Yes	No	No	No	Yes	No	No	No
Rhinitis	Yes	No	Yes	No	No	No	Yes	No	No	No
Dose inhaled steroid (µg·day−1 of fluticasone equivalent dose)	2000	400	800	750	1000	800	2000	1000	800	1000
Oral steroids	No	No	No	No	Yes	No	No	No	No	No
FEV1/FVC (%)	68	64	41	79	33	58	57	91	63	73
BHR	Yes	Yes	No	No	No	No	No	No	Yes	No
FEV1 (L)	1.69	1.84	0.80	0.80	0.70		0.88	1.20	1.83	1.73
FEV1 (%)	71	92	36	33	26	70	52	40	74	103
TLC (%)	NA	108	119	64	121	111	96	64	107	102
RV (%)	NA	132	198	115	229	152	129	106	123	98
FENO (ppb)	6	NA	NA	NA	NA	NA	NA	NA	6	NA
Air trapping	Yes	No	Yes	No	Yes	No	Yes	Yes	Yes	No
Number of pulmonary nodules	>10	2–5	>10	2–5	5–10	2–5	2–5	2–5	2–5	>10
Blood eosinophils (109 cells·L−1)	0.21	0.23	0.84	0.15	0.24	0.14	0.06	0.07	0.09	0.59
Total IgE (kUI·L−1)	15	NA	22	37	50	NA	15	NA	241	NA
Somatostatin analogue	Yes	No	No	No	Yes	No	No	No	No	No
Effect on cough	Yes				No
mTor inhibitor	No	No	Yes	No	Yes	No	No	No	No	No
Effect on cough			Yes		No

Cough was assessed at 6 months after therapy initiation. Cough improvement or no cough change was subjectively collected from patients’ testimonies. BMI: body mass index; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; BHR: bronchial hyperresponsiveness; TLC: total lung capacity; RV: residual volume; F_ENO: fractional exhaled nitric oxide; F: female; M: male; NA: not assessed.